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Background: The present cross-sectional study examined the associations of individual 
metabolic factors and age with the short-term memory and perceptual capacity in 472 
healthy Asian men. Methods: The symbol digit and digit span tests from the Swedish 
Performance Evaluation System were used to assess the perceptual capacity and memory 
cognitive domains. Linear regression with the stepwise method, and multivariate 
analyses of the General Linear Model with the Bonferroni correction for multiple 
comparisons were carried out with the SPSS 21.0 package. Results: High blood pressure 
and HDL were not significantly associated with either short-term memory or perceptual 
capacity. Age and glucose level were negatively associated but regular physical exercise 
was positively associated with perceptual capacity. On the other hand, high triglyceride 
level (TG) was positively associated but high waist/height ratio was negatively associated 
with short-term memory. When men without any component of the metabolic syndrome 
(MetS), were compared with men with one, two or three or more components of MetS, 
no significant differences in cognitive performance were noted. Conclusion: Not all the 
metabolic factors were significantly associated with short-term memory or the perceptual 
capacity domains. Those that were did not show a sufficiently consistent pattern of 
association to support a role for MetS as a whole in cognitive decline with aging. It may 











Age is associated with a decline in cognition and as the population ages every 
society is faced with the challenge of addressing the increasing number of elderly with 
cognitive impairment and/or dementia [1]. Different domains of human cognition are 
thought to be variably affected by behavioral, psychological, lifestyle, environmental 
and other factors including metabolic syndrome (MetS) risk factors [2-15].  
 
Metabolic syndrome (MetS) is not a disease but comprises a group of risk 
factors including high blood pressure, impaired levels of blood cholesterol, altered 
glucose metabolism or insulin resistance, and obesity. These risk factors together 
increase the likelihood of heart disease, stroke, peripheral vascular disease, and type 2 
diabetes. Proposed definitions of MetS include those by the World Health Organization 
[16], the European Group for the Study of Insulin Resistance (EGIR) [17], the US 
National Cholesterol Education Program (ATPIII) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults [18] and one 
introduced in 2005 by the International Diabetes Federation (IDF) [19].  
 
In Australia, based on the ATPIII definition of MetS, the overall prevalence is 22.1% 
with the prevalence in men higher than in women (24.4% versus 19.9%, respectively) 
[20]. Numerous studies have shown that MetS can adversely affect cognition and 
increase the risk for dementia [11-15]. When coupled with obesity, MetS is associated 
with a greater decline in cognitive performance [21]. However, the association of MetS 
with cognitive decline is equivocal. Differences were observed when different cognitive 
domains were assessed and when different cognitive function tests with varying 
sensitivity were employed. MetS was significantly associated with memory and 
visuospatial but not with the executive cognitive domains [22]. Gender, age, educational 
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levels, and race have also been shown to have a bearing on cognitive performance. It has 
been shown that MetS was associated with an increased risk of cognitive decline in 
adults aged between 65 and 74 year, but in the oldest of old (those > 80y), the association 
disappeared [22-25]. Other studies have variably noted that MetS had a gender-
dependent association with cognition, affecting cognition more in men [26, 27], more in 
women [12], while in others, no gender difference was noted [11]. Most of the earlier 
studies evaluated subjects with MetS, those with at least 3 out of the 5 risk factors and 
compared the cognitive performance of those without MetS. However, the control group 
may not be a true control group in that subjects may have none or up to 2 MetS risk 
factors. Relatively few studies evaluated the association of the individual components of 
the metabolic syndrome with cognition [13]. It is not valid to assume that every risk 
factor of the MetS is associated with cognition, in the same manner and to the same 
degree. In this cross-sectional study we sought to clarify the association of the individual 














SUBJECTS, MATERIALS AND METHODS 
Subjects  
This study involved analyses of data collected from a group of 472 men. Details of 
recruitment of the subjects have been reported in several earlier publications [28, 29]. 
Subjects were healthy men, aged between 29y to 72y living in the community.  
Methodologies  
Each subject answered a self-administered and investigator-guided questionnaire. Questions 
asked include their medical, dietary, social, sex, and family histories and other histories 
regarding consumption of hormones, supplements and medication and the types and frequency 
of beverages consumed.   
 
Biochemical measurements  
An overnight 12h fasting blood sample was collected, and serum levels of cholesterol (TC) and 
triglycerides (TG) were measured using an automated procedure. High density lipoprotein-
cholesterol (HDL) was determined after precipitation of apolipoprotein B-containing 
lipoproteins with sodium phosphotungstate and magnesium chloride [30]. Low density 
lipoprotein cholesterol (LDL) was computed according to the following formula: LDL = TC –
(HDL + [TG x 0.45]). The ratio of TC to HDL (TC/HDL) was used as the atherogenic index 
[31].  Fasting glucose level was measured using the hexokinase method on an Abbott Architect 
automated platform (Abbott Laboratories, Abbott Park, Illinois, U.S.A). 
 
Whole body DEXA scan 
Every man had a whole body scan using the DEXA Hologic, Bedford, MA, USA [28]. The 
total body fat (%BF) based on the Siri formula used by the DEXA machine was used in the 




Bodyweight (Wt) in kilogram was measured without shoes using an electronic measuring 
scale. Height (Ht) was taken to the nearest centimeter. The body mass index (BMI) was 
calculated as bodyweight in kilogram divided by height in meter squared. Waist circumference 
(W) in centimeter was measured midway between the lower costal margin and iliac crest 
during the end-expiratory phase, while hip circumference (H) was measured in centimeters. In 




Brachial systolic (Sys) and diastolic (Dia) blood pressures were measured by trained clinical 
researchers using a standardized manual sphygnomanometric method after subjects had five 
minutes of rest in the supine position. Both blood pressures were recorded as millimeter of 
mercury (mmHg). 
 
Cognitive function tests 
 
Two tests from the Swedish Performance Evaluation System (SPES), the Symbol Digit 
for perceptual capacity and Digit Span for short-term memory, were used in the study 
[32].  
Symbol Digit – The Symbol Digit is a test of perceptual capacity which includes 
matching, memory and the speed of processing. In one row, a key to this coding task is 
given by the pairing of symbols with randomly arranged digits, 1 to 9. The task is to key 
in as fast as possible the digits corresponding to the symbols presented in random order 
in a second row. Each set consists of nine pairs of randomly arranged symbols and digits, 
and a total of 10 sets are presented. Performance is evaluated as the mean reaction time 
(msec) (RT) and the number of errors (Err) for the last 54 pairs of the test. Symbol digit 
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tests the individual’s ability to interpret and correctly match what he sees as well as the 
speed of his mental perception. It also involves hand-eye coordination. The two 
components of this test are reaction time (RT) and the number of errors (Err) [32]. 
 
Digit Span – The Digit Span is a test of short-term memory capacity. In this test, a series 
of digits is presented on the screen. The digits are presented one at a time with a 1-second 
presentation time, and the task is to reproduce the series on the keyboard. Depending on 
the answer, the length of the following series is either increased or decreased. The test 
starts with a series of three digits and it is terminated after six incorrect answers. 
Performance is evaluated as the maximum string of numbers (DSpan) that the subject 
could remember successfully. A longer DSpan indicates a better short term visual 
memory [32]. 
 
The digit symbol and digit span are computer-based tests. All participants underwent a 
familiarization trial test before the actual scorings were recorded.    
 
Exercise scores and groupings 
 
The type, duration and frequency/week of exercise for each participant were collated from data 
from the self-administered and investigator-guided questionnaire. The intensity of the physical 
exercise was scored using the Metabolic Equivalent of Task (MET) for each exercise type. The 
scoring took into account the duration of each exercise episode and the frequency of the 
exercise per week to derive an exercise score. In accordance with the guidelines for Americans 
[33], the MET cut-off values were as follow: light intensity (<3 MET), moderate intensity (3–6 
MET) and high intensity (>6 MET). The total exercise score per week was expressed as 
metabolic equivalent-min (MET-min). A total exercise score for each individual was derived 
from data from the self-administered questionnaire. Each exercise type was given a value for 
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MET. For example, jogging and walking were assigned a MET of 8.5 and 3.0, respectively. An 
individual who jogs four times a week and each time for 45 min will have a total score/week 
(ExSc) of 1530 (8.5 x 45 x 4) MET-min. A person who walks for 60 min and six times per 
week will have an ExSc of 1080 (3 x 60 x 6) MET-min. Those who did not exercise routinely 
were given an arbitrary score of zero MET-min. By this scoring formula, all exercise type can 
be given a score which is used to indicate how intensely an individual was exercising as a 
lifestyle habit. Only when the exercise regime was carried out for at least 6 months was it 
considered a lifestyle habit. By using this index of intensity of exercise, association studies 
with various exercise regimes as lifestyle habits could be evaluated.   
 
The intensities of exercise were categorized into three groups: ExGp1 (no exercise, MET-min 
= 0), ExGp2 (moderate intensity, MET-min = 53 - 1230), ExGp3 (high intensity, MET-min = 
1260 - 4320) The 75 percentile of all men with an exercise score >0 MET-min was 1250. 
Therefore ExGp3 represented those men who have had exercise intensity above the 75 
percentile. 
 
Age groups (AgeGp) 
 
Men were categorised into 4 age groups as follows: AgeGp1 (29-40y), AgeGp2 (41-
50y), AgeGp3 (51-60y) and AgeGp4 (61-72y). The decade interval in age groupings was 
commonly used in many of our earlier studies [28, 29, 34, 35] 
 
Metabolic Syndrome Groupings 
 
The most commonly used NCEP ATPIII definition of MetS [18] was used for the 
purpose of this study. It is a simple scoring system with no single dominant component, 
and is used by several studies evaluating the association of MetS with human cognition 
[13, 26, 36]. In the present study, we evaluated the association of MetS as a whole as 
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well as the individual risk components with the different parameters of cognition. Povel 
et al [37] had suggested that using the NCEP ATPIII definition to compose one entity 
from MetS risk factors, MetS could predict Type 2 Diabetes and cardiovascular disease. 
However, it may not necessarily be applicable to cognition assessment. An earlier study 
in fact found that MetS as an entity did not show a significant association with cognition, 
while some of the individual risk components of MetS did [13].   
 
According to the recommendations of the NCEP ATP III [18], the 5 risk factors of MetS 
were defined as follows: 
 
High density lipoprotein cholesterol (HDL) <1.03mmol/l    
Fasting glucose level (GLU) >5.6mmol/l 
Systolic blood pressure/diastolic blood pressure - B/P >130/>85 mmHg   
Triglyceride level (TG) > 1.7mmol/l 
Waist circumference (W) >92.5cm (W of >92.5cm was the index for central obesity 
found to be appropriate for the local population) [38].  
 
Each risk factor of the MetS and other metabolic parameters was divided into two 
categories, one above and the other below the recommended cut-off points. Other indices 
of obesity: body mass index (BMI), the percent body fat (%BF) as derived from the 
whole body DEXA scan using the Siri formula, waist/hip ratio (WH), and waist/height 
ratio (WHt) were included in the analyses. We also evaluated other lipids and 
lipoproteins in the analyses including total cholesterol (TC), low density lipoprotein 
cholesterol (LDL) and the TC/HDL ratio. Therefore the groups used in the multivariate 




TG groups (TGGp):  TGGp1 <1.7 mmol/l  TGGp2 >1.7mmol/l 
HDL groups (HDLGp):  HDLGp1 >1.03 mmol/l HDLGp2<1.03mol/l 
TC groups (TCGp):   TCGp1 <6.2 mmol/l  TCGp2 >6.2 mmol/l 
LDL groups (LDLGp):  LDLGp1 <4.14 mmol/l LDLGp2 > 4.14 mmol/l 
TC/HDL groups (TC/HDLGp):TC/HDLGp1 <5.0  TC/HDLGp2 >5.0 
GLU groups (GLUGp):  GLUGp1 <5.6mmpl/l  GLUGp2 >5.6mmol/l 
%BF groups (%BFGp):  %BFGp1 <25%  %BFGp2 >25% 
BMI Groups (BMIGp):  BMIGp1 <27kg/m
2
  BMIGp2 >27kg/m
2
 
W groups (WGp):  WGp1 <92.5cm  WGp2 >92.5 
W/H ratio groups (WHGp): WHGp1 <0.94  WHGp2 >0.94 
W/Ht ratio groups (WHtGp): WHtGp1 <0.55  WHtGp2 >0.55 
 
The indices for obesity were established earlier for this same sample of men [38]. The 
World Health Organization recommended a BMI of 30kg/m
2
 as the cut-off value for 
obesity [39]. However, we have shown that a BMI of 30kg/m
2
 correlated very poorly 
with a measure of obesity based on DEXA-derived percent total body fat of 25% in the 
sample of Singaporean men [38]. In this study, the DEXA-derived percent body fat as a 
measure of obesity and the more appropriate BMI of 27kg/m2 were used in the analyses. 
The cut-off values for W, W/H and W/Ht of 92.5cm, 0.94 and 0.55 appropriate for the 
Singaporean men [38] differed from those in the Caucasian population.  
 
No of MetS symptom groups (Msym) 
 
Subjects were categorised into four Msym groups based on the number of metabolic risk 
factors they had as follows: 
 




Msym1    1 risk factor out of 5 listed for MetS 
 
Msym2 2 risk factors out of 5 listed for MetS  
 





Statistical analyses were performed using SPSS for windows version 21.0. Basic 
descriptive statistics and the Multivariate analyses of the General Linear Model coupled 
with the Bonferroni correction for multiple comparisons were used on continuous 
measurements. All the individual risk factors of MetS, other metabolic factors together 
with age, and exercise score (MET-min) were subjected to multiple linear regression 
analyses. To evaluate the parameters which were independently correlated to the 
cognitive parameters, the “stepwise” method of linear regression analyses was adopted. 
Significant correlation was set at a p-value of <0.05. 
 
Initial analyses showed that age, MET-min, TG, GLU and WHt were independently 
associated with cognitive functions. Hence, in the final analyses, all multivariate analyses 













Table 1 shows the metabolic parameters included in the linear regression analyses using 
the stepwise method, age, exercise score (MET-min), triglyceride level (TG), fasting 
glucose level (GLU) and the anthropometric parameter of WHt that were independently 
and significantly correlated with one or two of the three measures of cognition studied. 
Age was associated with longer RT in the perceptual capacity domain, while high GLU 
was associated with poorer perceptual capacity, with higher Err and longer RT (Table 1). 
Higher MET-min was associated with shorter RT (Table 1). High TG, on the other hand, 
was associated with better short–term memory, with longer DSpan (Table 1). WHt, an 
index of central obesity, was negatively associated with DSpan (Table 1). No significant 
correlation with the cognitive parameters was noted for other components of the 
metabolic syndrome: blood pressure, waist circumference, HDL and other indices of 
obesity BMI, W, WH, and %BF and LDL, TC and TC/HDL. 
 
It was shown with the multivariate analyses that older aged men had longer RT than 
younger men. Men above the age of 60y had significantly longer RT, by up to 12.9% 
when compared to men 40 y old or younger (Table 2). Men who had a regular physical 
exercise regime as a lifestyle habit (ExGp2), on the other hand, had shorter RT, by up to 
6.8%, when compared to men without a regular physical exercise regime (ExGp1, Table 
2). Table 2 also shows that age is significantly associated with some of the metabolic 
factors. Higher systolic and diastolic blood pressure, WH and WHt and fasting glucose 
levels were associated with age, while the number of risk factors for MetS was higher in 
older men (Table 2).  
 
Of the five components of MetS, only two had significant association with cognitive 
functions when using the multivariate analyses. High fasting glucose, >5.6mmol/l 
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(GLUGp2) was associated with higher Err, but not with RT in the perceptual capacity 
test as compared to men with GLU below 5.6mmol/l (GLUGp1), and was not associated 
with short-term memory (Table 3). High TG, >1.7mmol/l (TGGp2), on the other hand, 
had a positive association with short-term memory; DSpan being about 3.9% longer but 
not significantly associated with perceptual capacity (Table 3). Of all the other metabolic 
factors evaluated, only high total body fat, > 25% (%BFGp2) was associated with poorer 
short-term memory, DSpan being shorter by 8.8% in obese men when compared with 
non-obese men (%BFGp1) (Table 3). No other metabolic factors were significantly 
associated with any of the 3 measures of the short-term memory and perceptual domains 
of cognition (Table 3). 
 
Regular physical exercise as a lifestyle habit was significantly associated with only the 
RT component of the perceptual capacity. A moderate to high intensity of exercise 
(ExGp2 & ExHGp3) was associated with lower RT when compared to men who did not 
have regular exercises (ExGp1) (Table 3). It is interesting to note that in the men studied, 
men aged above 60y old were exercising more intensely than all the younger men (Table 
2).   
 
Out of 472 subjects who had all the essential parameters for evaluation of the metabolic 
syndrome, 41.5% had no MetS symptom, 32.7% had 1 symptom, many of these men had 
high TG >1.7mmol/l. About 20.3% had 2 symptoms, and 5.5% had 3 to 4 symptoms. 
When compared to men without any MetS risk factor (Msym0), men with 1 (Msym1), 2 
(Msym2) and 3 or more symptoms (Msym3) showed no significant differences in any of 






Aging is associated with a decline in cognitive performance [40, 41]. However, the onset 
and rate of decline vary according to which cognitive domain is evaluated. In the present 
study, a significantly longer RT for perceptual capacity was noted only in men aged 50 
years and above; and the RT appeared to be higher in men above 60y. On the other hand, 
age was not associated with a decline in the short-term memory domain in men up to 72 
years old.  
 
A regular physical exercise regime as a lifestyle habit is beneficial to the RT component 
of the perceptual capacity. Both moderate (ExGp2) and intense (ExGp3) physical 
exercises were associated with shorter RT than in men who were not exercising regularly 
(ExGp1). These observations imply the importance of a physically active lifestyle in 
warding off or attenuating the age-associated decline in cognitive performance [8, 9]. We 
therefore advocate the promotion of a lifestyle habit of physical exercises as an 
important, non-invasive modality to help maintain cognitive health in aging men. 
 
Association of metabolic syndrome and  with cognition has been equivocal, with studies 
showing negative, positive or neutral associations [10-13, 21, 23]. Gender and age may 
complicate the associations of MetS and cognition [11, 12, 22-27]. Hence, the 
observations noted in the present study are applicable only to men between the ages of 29 
to 72 y and specific to the perceptual and short-term memory cognitive domains. We 
have shown that individually, not all the risk factors of the MetS had significant 
association with the two cognitive domains evaluated. Those that did showed 
associations with different cognitive domains and in opposite directions. High fasting 
glucose was negatively associated with the perceptual capacity, both in terms of the 
number of errors as well as the retention time, an observation that is similar to those of an 
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earlier paper [13]. High TG levels, on the other hand, were positively associated with 
short-term memory. High WHt ratio was negatively associated with the short-term 
memory. Contrary to the earlier study [13], no significant and independent correlations 
were noted for the other two components of the MetS, namely systolic and diastolic 
blood pressure, and HDL-C. No significant and independent correlations were noted for 
the other metabolic factors evaluated except for percent total body fat. Obesity in men 
was associated with poorer short-term memory when compared to non-obese men.  
 
Low density lipoprotein cholesterol (LDL) and HDL are major transport lipoproteins of 
cholesterol and together with TG are independently associated with cardiovascular 
disease [42] and possibly cognitive impairment [43]. Some studies have shown 
conflicting associations of LDL, HDL and TG with cognition. Other studies have shown 
an association of high LDL, HDL and TG with decline in cognitive performance [44-47]. 
Still other studies have shown no association of high LDL, HDL and TG with cognitive 
functions [48-51]. Opposite associations were also noted for high LDL and HDL [52-54]. 
The present study found that high levels of TG, in contrast to earlier studies [47, 55] were 
associated with better short-term memory. Another recent study has shown that higher 
levels of LDL were associated with better general cognitive performance and processing 
speed [56]. It is possible that the conflicting findings of the association of LDL, HDL and 
TG may be due, in part, to age, gender, cognition outcome measures, levels of 
lipoproteins and lipids and varying degrees of adjustments of other confounding factors 
such as adjusting for exercise intensity, and/or other metabolic factors. Further research 
is needed to clarify the roles of the individual metabolic factors with cognition.  
 
We have shown that different components of the MetS may be associated with different 
cognitive domains and in different directions. Therefore, it is not unexpected that we 
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found that dichotomizing men into MetS or Non-MetS overall did not predict scores in 
the cognitive parameters studied. This is especially true when the analyses were adjusted 
for confounding factors including, age and exercise intensity, etc. This observation was 
similar to that of an earlier paper [13]. Since different components of the MetS have none 
or varying associations with cognition it is therefore not meaningful to study the 
relationship between MetS as a single construct and cognition. We need to clarify the 
role of each component of MetS in cognitive performance, in order to establish 
modalities to help enhance cognitive performance and/or reduce its decline with age. 
 
A limitation of this study is that it is a cross-sectional study; hence no causal effect is 
attributable to the observed associations. The number of cases in some groupings was 
small and may have limited the validity of the findings. Only two cognitive domains, the 
perceptual and memory domains, were studied, hence cross comparisons with studies 
with other domains of cognition could not be made. On the other hand, a positive 
contribution of the present study is the involvement of a relatively wide age range (29 
years to 72 years) of Asian men who were healthy with no known illnesses that might 
mar the actual association of the metabolic factors with cognition. 
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Table 1: Parameters with significant regression with the three cognitive parameters 
(number of errors (ERR), retention time (RT) and maximum length of string (DSpan) 
based on linear regression analyses using the “stepwise” method for all continuous 
variables including age, MET-min, %BF, systolic B/P, Diastolic B/P, BMI, waist 
circumference (W), waist/hip ratio (WH), waist/height ratio (WHt), total cholesterol 
(TC), high-density lipoprotein-C (HDL), low-density lipoprotein-C (LDL), TC/HDL 








Err GLU 0.175 <0.001 
    
RT (msec) Age 0.285 <0.001 
 MET-min -0.116 0.015 
 GLU 0.109 0.024 
    
DSpan TG 0.138 0.006 






























Table 2: The mean (+SE) of exercise score, metabolic and anthropometric parameters and 3 measures of cognitive 
function Err, RT and DSpan in the different age groups (MET-min, WHt, TG and GLU were covariates for 










Err 1.87+0.299 1.59+0.173 1.33+0.187 1.68+0.287 
RT(msec) 2279+50
a 2329+30b 2454+31c 2574+48 
DSpan 6.98+0.162 7.05+0.095
d 6.94+0.103 6.55+0.15 
     
Met-min 436+98
e 577+58e 575+62e 970+92 
     
Systolic (mmHg) 123+1.9
f 124+1.1f 128+1.1f 137+1.7 
     
Diastolic (mmHg) 77.7+1.2
g 78.2+0.7g 80.5+0.7 82.7+1.1 
     
Ht (cm) 171.4+0.76
h 169.5+0.42i 167.6+0.45 166.3+0.68 
     
Wt (Kg) 70.2+1.28 68.5+0.71 67.8+0.75 65.7+1.14 
     
BMI (kg/m
2
) 23.9+0.39 23.8+0.21 24.1+0.23 23.7+0.35 
     
W (cm) 83.9+0.91 83.7+0.51 85.3+0.54 85.9+0.82 
     
H (cm) 97.0+0.73
j 95.6+0.40 95.6+0.43 94.0+0.65 
     
W/H 0.87+0.006
k 0.88+0.003l 0.89+0.00m 0.91+0.005 
     
W/Ht 0.49+0.00
n 0.49+0.003o 0.51+0.003 0.52+0.005 
     
TC (mmol/l) 5.77+0.132 5.75+0.073 5.72+0.78 5.80+0.118 
     
TG (mmol/l) 1.31+0.092 1.46+0.051 1.56+0.054 1.34+0.082 
     
HDL(mmol/l) 1.32+0.039 1.33+0.022 1.32+0.023 1.42+0.035 
     
LDL (mmol/l) 3.87+0.121 3.77+0.067 3.71+0.071 3.77+0.108 
     
TC/HDL 4.55+0.144 4.50+0.080 4.54+0.085 4.23+0.129 
     
GLU (mmol/l) 4.91+0.93 4.79+0.051
p 4.99+0.055 5.22+0.083 
     
No. Metsym 0.51+0.12
q 0.71+0.07r 0.92+0.07 1.07+0.11 
a= AgeGp1 is significantly lower than AgeGp3 & AgeGp4 (p = 0.003, <0.001) 
b= AgeGp2 is significantly lower than AgeGp3 & AgeGp4 (p = 0.008, <0.001) 
c= AgeGp3 is significantly lower than AgeGp4 (p = 0.036) 
d= AgeGp2 is significantly higher than AgeGp4 (p = 0.036) 
e= AgeGp1, AgeGp2 & AgeGp3 are significantly lower than AgeGp4 (p =<0.001, 0.002, 0.002) 
f= AgeGp1, AgeGp2 & AgeGp3 are significantly lower than AgeGp4 (p = <0.001, <0.001, <0.001) 
g= AgeGp1 & AgeGp2 are significantly lower than AgeGp4 (p = 0.018, 0.004) 
h= AgeGp1 is significantly higher than AgeGp3 & AgeGp4 (p = <0.001, <0.001) 
i= AgeGp2 is significantly higher than AgeGp3 & AgeGp4 (p = 0.015, <0.001) 
j= AgeGp1 is significantly higher than AgeGp4 (p = 0.018) 
k= AgeGp1 is significantly lower than AgeGp3 & AgeGp4 (p = <0.001, <0.001) 
l= AgeGp2 is significantly lower than AgeGp3 & AgeGp4 (p = 0.002, <0.001) 
m= AgeGp3 is significantly lower than AgeGp4 (p = 0.004) 
n= AgeGp1 is significantly lower than AgeGp3 & AgeGp4 (p = 0.003, <0.001) 
p= AgeGp2 is significantly lower than AgeGp3 & AgeGp4 (p = 0.004, <0.001) 
p= AgeGp2 is significantly lower than AgeGp3 & AgeGp4 (p = 0.036, <0.001) 
q= AgeGp1 is significantly lower than AgeGp3 & AgeGp4 (p = 0.024, 0.004) 
r= AgeGp2 is significantly lower than AgeGp4 (p = 0.031) 
 
25 
Table 3: The mean (+SE) of Err, RT and DSpan in the various metabolic factors (Analyses adjusted with the  
Table 3: Associations of exercise groups and various metabolic factors with the 3 measures of cognitive function 
using the multivariate analyses with the appropriate covariates including, MET-min, age, WHt, TG, and Glucose 
levels (GLU). 
 ExGp1 (141) ExGp2 (143) ExGp3 (186)  
Err 1.95+0.196 1.39+0.194 1.45+0.171  
RT (msec) 2503+32
a 2360+32 2365+28  
DSpan 6.88+0.107 6.99+0.106 6.89+0.093  
     
 %BFGp1(411) %BFGp2(19)   
Err 1.57+0.115 1.69+0.551   
RT (msec) 2416+19 2268+90   
DSpan 6.93+0.063
b 6.28+0.298   
     
 WGp1 (421) WGp2 (49)   
Err 1.58+0.119 1.53+0.372   
RT (msec) 2415+19 2359+61   
DSpan 6.92+0.065 6.77+0.204   
     
 WHGp1(423) WHGp2 (47)   
Err 1.58+0.114 1.59+0.370   
RT (msec) 2402+19 2430+61   
DSpan 6.93+0.062 6.80+0.202   
     
 WHtGp1(399) WHtGp2 (71)   
Err 1.56+0.116 1.72+0.279   
RT (msec) 2400+19 2431+46   
DSpan 6.95+0.064 6.75+0.153   
     
 BMIGp1 (436) BM1Gp2 (15)   
Err 1.60+0.110 0.479+0.593   
RT (msec) 2401+18 2365+97   
DSpan 6.92+0.060 6.55+0.325   
     
 BPGp1(371) BPGp2 (77)   
Err 1.55+0.121 1.65+0.268   
RT (msec) 2418+20 2329+44   
DSpan 6.91+0.065 6.79+0.146   
     
 HDLGp1(74) HDLGP2 (396)   
Err 1.46+0.280 1.60+0.117   
RT (msec) 2396+46 2406+19   
DSpan 7.06+0.153 6.89+0.064   
     
 TGGp1 (328) TGGp2 (142)   
Err 1.62+0.130 1.49+0.199   
RT (msec) 2416+21 2379+33   
DSpan 6.84+0.071
c 7.11+0.110   
     
 GLUGp1 (427) GLUGp2 (43)   
Err 1.49+0.113
d 2.48+0.370   
RT (msec) 2397+18 2486+60   
DSpan 6.94+0.062 6.71+0.201   
     
No. METS symptoms Msym0 (196) Msym1 (154) Msym2 (96) Msym3 (26) 
Err 1.50+0.18 1.46+0.19 1.75+0.29 2.14+0.51 
RT (msec) 2429+29 2382+31 2385+48 2382+85 
DSpan 6.91+0.10 6.83+0.102 6.97+0.16 6.95+0.28 
 
a= ExGp1 is significantly higher than ExGp2 & ExGp3 (p = 0.005, 0.004) 
b= %BFGp1 is significantly higher than %BFGp2 (p = 0.043) 
c= TGGp1 is significantly lower than TGGp2 (p = 0.043) 
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